Teresa Amaral, Vice-Chair of SAG Oncology at the European Medicines Agency, Head of Early Phase Clinical Trials, Skin Cancer and Sarcoma Program at Institute Strauss, shared a post on LinkedIn:
“An important/worth reading report has just been published: ‘The economic impact of industry clinical trials across Europe‘.
Clinical trials and clinical research have a major impact on society, including an economic impact.
From this report, I would highlight 3 points:
1. €35.7B annual GVA and 165k jobs supported – Oncology is a major driver of trial activity, cancer centres are significantly involved in trial-related activities/generated employment. Research-active hospitals with clinicians involved in research appear to have greater awareness and faster adoption of newly licensed therapies.
2. Decline in Europe’s share of global trials: Despite the strong base, Europe’s global position has weakened. Fewer (oncology) trials = slower access to new therapies and reduced global competitiveness of EU research centres.
3. Increasing trial activity could add €4B (11.1% increase) – 18B (50% increase) GVA. Trials in Oncology-with high complexity and value-would capture a (large) share of growth.
The report also provides an overview of 3 potential scenarios (and respective impact) of an increased number of trials in Europe:
1. by 11.1% – in line with EMA target,
2. by 25% – increasing back to the 2013 level,
3. by 50% – to ‘catch up‘ with growth in China and North America.
The full report is very much worth reading, independently of how/what we think about the topic. It ends like this: With the proposed EU Biotech Act, Europe has a unique opportunity to strengthen its clinical research ecosystem and regain global competitiveness in life sciences.”
Other articles featuring Teresa Amaral on OncoDaily.